Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
James D. Chalmers, David Cipolla, Bruce Thompson, Angela M. Davis, Anne O'Donnell, Gregory Tino, Igor Gonda, Charles Haworth, Juergen Froehlich
European Respiratory Journal 2020 56: 2000110; DOI: 10.1183/13993003.00110-2020
James D. Chalmers
1University of Dundee, Dundee, UK
David Cipolla
2Insmed Incorporated, Bridgewater, NJ, USA
3Aradigm Corporation, Hayward, CA, USA
Bruce Thompson
4Theta Hat Statistical Consultants LLC, Owings Mills, MD, USA
Angela M. Davis
5Grifols, Research Triangle Park, NC, USA
Anne O'Donnell
6Georgetown University, Washington, DC, USA
Gregory Tino
7University of Pennsylvania, Philadelphia, PA, USA
Igor Gonda
3Aradigm Corporation, Hayward, CA, USA
8Respidex LLC, Dennis, MA 02638, USA
Charles Haworth
9Royal Papworth Hospital and Department of Medicine, University of Cambridge, Cambridge, UK
Juergen Froehlich
3Aradigm Corporation, Hayward, CA, USA
Vol 56 Issue 4
Table of Contents
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
James D. Chalmers, David Cipolla, Bruce Thompson, Angela M. Davis, Anne O'Donnell, Gregory Tino, Igor Gonda, Charles Haworth, Juergen Froehlich
European Respiratory Journal Oct 2020, 56 (4) 2000110; DOI: 10.1183/13993003.00110-2020
Changes in respiratory symptoms during 48-week treatment with ARD-3150 (inhaled liposomal ciprofloxacin) in bronchiectasis: results from the ORBIT-3 and -4 studies
James D. Chalmers, David Cipolla, Bruce Thompson, Angela M. Davis, Anne O'Donnell, Gregory Tino, Igor Gonda, Charles Haworth, Juergen Froehlich
European Respiratory Journal Oct 2020, 56 (4) 2000110; DOI: 10.1183/13993003.00110-2020